Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy for NA-resistant chronic hepatitis B (CHB). Methods: In this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA >60 IU/mL) to ADV+NA therapy for NA resistance were randomly allocated to receive TDF plus NA (TDF+NA group, n=16) or to continue their current therapy (ADV+NA group, n=16). The primary end point was the proportion of patients with complete virological response (CVR, defined as serum HBV DNA <60 IU/mL) at 48 weeks. Results: The median age was 52 years (16 men), and 28 were positive for hepatitis B e antigen (HBeAg). The baseline characteristics did not differ significantly between the two groups. The proportion with CVR was significantly higher in the TDF+NA group than in the ADV+NA group at 24 weeks (81.3% vs. 25.0%, P=0.001) and 48 weeks (87.5% vs. 37.5%, P=0.002). Furthermore, a decrease in the serum HBV DNA level of >2log10 IU/mL was more likely in the TDF+NA group at both 24 and 48 weeks (68.8% vs. 56.3%, P=0.014 vs. 81.3% vs. 56.3%, P=0.001, respectively). During the follow-up, the rate of HBeAg seroconversion was higher in the TDF+NA group than the ADV+NA group (12.5% vs. 6.25%, P=0.640), as was that for the hepatitis B surface antigen (6.25% vs. 0%, P=0.080). No serious adverse events due to antiviral agents occurred. Conclusions: In patients exhibiting suboptimal responses to ADV+NA therapy for NA-resistant CHB, switching from ADV to TDF might provide better virological outcomes. (Clin Mol Hepatol 2016;22:443-449)
Abstract
Background/Aims: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy for NA-resistant chronic hepatitis B (CHB). Methods: In this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA >60 IU/mL) to ADV+NA therapy for NA resistance were randomly allocated to receive TDF plus NA (TDF+NA group, n=16) or to continue their current therapy (ADV+NA group, n=16). The primary end point was the proportion of patients with complete virological response (CVR, defined as serum HBV DNA <60 IU/mL) at 48 weeks. Results: The median age was 52 years (16 men), and 28 were positive for hepatitis B e antigen (HBeAg). The baseline characteristics did not differ significantly between the two groups. The proportion with CVR was significantly higher in the TDF+NA group than in the ADV+NA group at 24 weeks (81.3% vs. 25.0%, P=0.001) and 48 weeks (87.5% vs. 37.5%, P=0.002). Furthermore, a decrease in the serum HBV DNA level of >2log10 IU/mL was more likely in the TDF+NA group at both 24 and 48 weeks (68.8% vs. 56.3%, P=0.014 vs. 81.3% vs. 56.3%, P=0.001, respectively). During the follow-up, the rate of HBeAg seroconversion was higher in the TDF+NA group than the ADV+NA group (12.5% vs. 6.25%, P=0.640), as was that for the hepatitis B surface antigen (6.25% vs. 0%, P=0.080). No serious adverse events due to antiviral agents occurred. Conclusions: In patients exhibiting suboptimal responses to ADV+NA therapy for NA-resistant CHB, switching from ADV to TDF might provide better virological outcomes. (Clin Mol Hepatol 2016;22:443-449)
참고문헌 (30)
- Ganem D, "Hepatitis B virus infection--natural history and clinical consequences", N Engl J Med, 350, pp.1118~1129 (2004)
- Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
- Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
- You CR, "Update on hepatitis B virus infection", World J Gastroenterol, 20, pp.13293~13305 (2014)
- Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
- Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
- Lai CL, "Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B", Clin Infect Dis, 36, pp.687~696 (2003)
- Lai CL, "Telbivudine versus lamivudine in patients with chronic hepatitis B", N Engl J Med, 357, pp.2576~2588 (2007)
- Lai CL, "A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B", Gastroenterology, 129, pp.528~536 (2005)
- Gwak GY, "A comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B: results after 2 years of treatment", Hepatol Int, 7, pp.106~110 (2013)
- Perrillo R, "Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus", Gastroenterology, 126, pp.81~90 (2004)
- 이현석, "라미부딘 내성 만성 B형 간염 환자에서 라미부딘과 아데포비어 병용치료", 대한내과학회지, 77(6), pp.716~722 (2009), 대한내과학회
- Kim SB, "Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B", J Gastroenterol Hepatol, 31, pp.241~247 (2016)
- Pol S, "First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice", J Viral Hepat, 19, pp.377~386 (2012)
- van Bömmel F, "Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside", nucleotide analogues, 2010, pp.51, 73~80
- European Association For The Study Of The Liver, "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Cho HJ, "Tenofovirbased rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance", J Med Virol, 87, pp.1532~1538 (2015)
- Yang DH, "Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine- resistant chronic hepatitis B patients", World J Gastroenterol, 21, pp.2746~2753 (2015)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update", Hepatol Int, 6, pp.531~561 (2012)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
- Lee JM, "Longterm adefovir dipivoxil monotherapy for up to 5 years in lamivudineresistant chronic hepatitis B", Antivir Ther, 15, pp.235~241 (2010)
- Ryu HJ, "Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudineresistant chronic hepatitis B", J Med Virol, 82, pp.1835~1842 (2010)
- Ghany MG, "Antiviral resistance and hepatitis B therapy", Hepatology, 49(5 Suppl), pp.S174~S184 (2009)
- Locarnini S., "Molecular virology and the development of resistant mutants: implications for therapy", Semin Liver Dis, 25(Suppl 1), pp.9~19 (2005)
- Si Hyun Bae, "Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea", Journal of Korean Medical Science, 20(5), pp.816~820 (2005), 대한의학회
- Yuen MF, "Treatment of chronic hepatitis B: Evolution over two decades", J Gastroenterol Hepatol, 26(Suppl 1), pp.138~143 (2011)
- Lampertico P, "Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine", Hepatology, 42, pp.1414~1419 (2005)
- Korean Association for the Study of the Liver, "KASL Clinical Practice Guidelines: Management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
- Lee YB, "Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B", Antimicrob Agents Chemother, 59, pp.972~978 (2015)